Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis
- 1 February 2018
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 93 (5) , 649-654
Abstract
The prognostic importance of genetic information in primary myelofibrosis (PMF) was recently highlighted in a study of over 1000 cytogenetically‐annotated patients; 5‐year survival rates were 8% for very high risk (VHR), 27% “unfavorable” and 45% “favorable” karyotype. The current study addresses the practice‐relevant question of whether or not allogeneic hematopoietic stem cell transplant (HCT) can overcome the detrimental survival effect of VHR or unfavorable karyotype. The study included 67 patients with PMF or secondary MF who received HCT at the Mayo Clinic and in whom pretransplant cytogenetic information was available. Dynamic international prognostic scoring system (DIPSS) risk distribution was 13% high, 66% intermediate‐2 and 21% intermediate‐1. Cytogenetic risk distribution was 11% VHR, 34% unfavorable and 55% favorable. At median post‐HCT follow‐up of 60 months for living patients (range 34‐170), 28 (42%) deaths were recorded. Five‐year survival was 62% and was not affected by VHR or unfavorable karyotype (P = .68). The salutary effect of HCT in patients with VHR or unfavorable karyotype was also apparent during analysis of a combined dataset that included a nontransplant cohort of 383 patients with PMF; multivariable analysis of the combined dataset (n = 450) resulted in HRs (95% CI) of 2.4 (1.6‐3.6) for absence of transplant, 3.3 (2.2‐4.8) for VHR karyotype, 1.6 (1.2‐2.1) for unfavorable karyotype, 2.9 (2.0‐4.2) for DIPSS high and 1.7 (1.4‐2.2) for DIPSS intermediate‐2. These observations were further confirmed by analysis of more stringently matched case‐control subset cohorts and provide the evidence for the therapeutic preference of HCT in cytogenetically high risk patients with MF.Keywords
This publication has 20 references indexed in Scilit:
- The different prognostic impact of type‐1 or type‐1 like and type‐2 or type‐2 like CALR mutations in patients with primary myelofibrosisAmerican Journal of Hematology, 2016
- Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemiaAmerican Journal of Hematology, 2016
- Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutationsAmerican Journal of Hematology, 2016
- Myeloproliferative neoplasms: Morphology and clinical practiceAmerican Journal of Hematology, 2015
- Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemiaAmerican Journal of Hematology, 2015
- Myeloproliferative neoplasms: A decade of discoveries and treatment advancesAmerican Journal of Hematology, 2015
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working groupLeukemia, 2015
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosisBlood, 2015
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion StatusJournal of Clinical Oncology, 2011
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood, 2010